<DOC>
	<DOCNO>NCT00545272</DOCNO>
	<brief_summary>This study evaluate dose response relationship among four dos indacaterol well placebo deliver via TWISTHALER® device .</brief_summary>
	<brief_title>A Dose Ranging Trial 4 Doses Indacaterol Delivered Via TWISTHALER® Device Adult Adolescent Patients With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>1 . Male female adult adolescent patient age 1275 year inclusive ( ≥1875 year depend upon regulatory and/or Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) /Research Ethics Board ( REB ) approval ) , sign Informed Consent Form prior initiation studyrelated procedure , include adjustment asthma medication prior Visit 1 . Patients legal age consent require Informed Consent Form sign patient 's parent / guardian . 2 . Patients asthma , diagnosed accord Global Initiative Asthma ( GINA ) guideline ( National Institute Health , National Heart , Lung Blood Institute , 2006 ) additionally meet follow criterion : 1 . Patients receive daily treatment inhale corticosteroid maximum dose per day indicate package leaflet , stable regimen month prior Visit 1 . 2 . Patients Forced Expiratory Volume one second ( FEV1 ) Visit 1 ≥50 % predict normal value patient . This criterion FEV1 demonstrate washout period least 6 hour short act β2agonist inhale , minimum 48 hour long act β2agonist . 3 . Patients demonstrate increase ≥12 % ≥200 mL FEV1 prebronchodilator value within 30 minute inhale total 200 µg/180 µg salbutamol/albuterol Metered Dose Inhaler ( MDI ) ( equivalent dose Dry Powder Inhaler [ DPI ] ) ( reversibility test ) . Reversibility demonstrate appropriate washout period least 6 hrs prior evaluation shortacting β2agonist . The administration salbutamol/albuterol reversibility test within 30 minute pre bronchodilator spirometry . Reversibility demonstrate Visit 1 Visits 1 2 , order patient include trial . Pregnant woman , nurse mother , female childbearing potential , regardless whether sexually active , use reliable form contraception . Patients Chronic Obstructive Pulmonary Disease ( COPD ) , current smoker , patient use tobacco product within 6 month period prior Visit 1 , smoke history great 10 pack year . Patients : 1. 's asthma likely deteriorate study ( include seasonal allergy ) , 2. hospitalize acute asthma attack/asthma exacerbation within 6 month prior Visit 1 , 3. emergency room visit asthma attack/asthma exacerbation within 6 week prior Visit 1 4. respiratory tract infection emergency room treatment asthma attack/asthma exacerbation within 4 week prior Visit 1 5 . Patients require use ≥8 inhalation per day short act B2agonist ( 100 µg/ 90 µg salbutamol/albuterol MDI equivalent dose DPI ) 2 consecutive day Screening Randomization . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>QMF</keyword>
	<keyword>indacaterol</keyword>
	<keyword>Twisthaler®</keyword>
</DOC>